Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
7
×
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
indiana blog main
indiana top stories
gene therapy
nonalcoholic steatohepatitis
cancer immunotherapy
clinical trials
deals
glaxosmithkline
startups
europe blog main
europe top stories
gilead sciences
investing
loxo oncology
What
cancer
7
×
roundup
7
×
bio
ahead
amid
bombast
cash
caught
coronavirus
days
debate
develop
discussion
drug
efforts
immunotherapy
meso’s
miss
pandemic
pfizer’s
presidential
promise
response
tuesday’s
vaccine
viewers
abbvie’s
advanced
allogene
ambien
american
annual
appetite
arrival
asco
attendees
attention
award
biofourmis
biotech
Language
unset
Current search:
cancer
×
roundup
×
" seattle blog main "
×
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
4 years ago
Bio Roundup: Award Winners, Lung Data, Dems on Drug Pricing & More
@xconomy.com
5 years ago
Bio Roundup: #JPM19 Notes, Loxo Buyout, Black Diamond’s Cash & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More